Literature DB >> 18353669

Three good reasons for heart surgeons to understand cardiac metabolism.

Torsten Doenst1, Heiko Bugger, Michael Schwarzer, Gloria Faerber, Michael A Borger, Friedrich W Mohr.   

Abstract

It is the principal goal of cardiac surgeons to improve or reinstate contractile function with, through or after a surgical procedure on the heart. Uninterrupted contractile function of the heart is irrevocably linked to the uninterrupted supply of energy in the form of ATP. Thus, it would appear natural that clinicians interested in myocardial contractile function are interested in the way the heart generates ATP, i.e. the processes generally referred to as energy metabolism. Yet, it may appear that the relevance of energy metabolism in cardiac surgery is limited to the area of cardioplegia, which is a declining research interest. It is the goal of this review to change this trend and to illustrate the role and the therapeutic potential of metabolism and metabolic interventions for management. We present three compelling reasons why cardiac metabolism is of direct, practical interest to the cardiac surgeon and why a better understanding of energy metabolism might indeed result in improved surgical outcomes: (1) To understand cardioplegic arrest, ischemia and reperfusion, one needs a working knowledge of metabolism; (2) hyperglycemia is an underestimated and modifiable risk factor; (3) acute metabolic interventions can be effective in patients undergoing cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353669     DOI: 10.1016/j.ejcts.2008.02.015

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Adenosine in cold blood cardioplegia--a placebo-controlled study.

Authors:  Anders Ahlsson; Claudio Sobrosa; Lennart Kaijser; Eva Jansson; Vollmer Bomfim
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15

Review 2.  Cardiac models in drug discovery and development: a review.

Authors:  Robert K Amanfu; Jeffrey J Saucerman
Journal:  Crit Rev Biomed Eng       Date:  2011

3.  Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy.

Authors:  Rongxue Wu; Hsiang-Chun Chang; Arineh Khechaduri; Kusum Chawla; Minh Tran; Xiaomeng Chai; Cory Wagg; Mohsen Ghanefar; Xinghang Jiang; Marina Bayeva; Frank Gonzalez; Gary Lopaschuk; Hossein Ardehali
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

Review 4.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 5.  GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects.

Authors:  Melanie Sulistio; Curtis Carothers; Mandeep Mangat; Mike Lujan; Rene Oliveros; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

Review 6.  Heart transplantation with donation after circulatory determination of death.

Authors:  Sarah L Longnus; Veronika Mathys; Monika Dornbierer; Florian Dick; Thierry P Carrel; Hendrik T Tevaearai
Journal:  Nat Rev Cardiol       Date:  2014-04-15       Impact factor: 32.419

7.  Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics.

Authors:  Abdulla Ahmed; Salaheldin Ahmed; Mattias Arvidsson; Habib Bouzina; Jakob Lundgren; Göran Rådegran
Journal:  ESC Heart Fail       Date:  2020-06-17

8.  The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial.

Authors:  Nigel E Drury; Neil J Howell; Melanie J Calvert; Ralf J M Weber; Eshan L Senanayake; Michael E Lewis; Jonathan A J Hyde; David H Green; Jorge G Mascaro; Ian C Wilson; Timothy R Graham; Stephen J Rooney; Mark R Viant; Nick Freemantle; Michael P Frenneaux; Domenico Pagano
Journal:  Eur J Cardiothorac Surg       Date:  2014-06-19       Impact factor: 4.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.